Steven Gregory Reed

Principal investigator.

Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
1993First federal award
$2.9MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Career record

Federal awards and patents by year

19932000
AwardsPatents
Federal awards as principal investigator

14 awards · $2.9M

DateAgencyAwardAmountCompany
May 5, 2000NIHNIH RC1
DEVELOPMENT OF A RECOMBINANT TUBERCULOSIS VACCINE
$26K—
Sep 30, 1999NIHSBIR/STTR Phase I
DEVELOPMENT OF IMPROVED SKIN TESTS FOR TUBERCULOSIS
$100K—
Sep 30, 1996NIHSBIR/STTR Phase I
MALARIA VACCINE ADJUVANT DEVELOPMENT
$98K—
May 1, 1996NIHSBIR/STTR Phase II
VACCINE FOR LEISHMANIASIS
$364K—
May 1, 1996NIHSBIR/STTR Phase II
VACCINE FOR LEISHMANIASIS
$352K—
Sep 30, 1995NIHSBIR/STTR Phase I
VACCINE FOR MYCOBACTERIUM TUBERCULOSIS
$100K—
Sep 1, 1995NIHSBIR/STTR Phase I
TGF-BETA ANTAGONISTS TO TREAT MYCOBACTERIAL INFECTIONS
$100K—
Sep 30, 1994NIHSBIR/STTR Phase II
DIAGNOSTIC ANTIGENS OF TRYPANOSOMA CRUZI
$374K—
Sep 30, 1994NIHSBIR/STTR Phase II
DIAGNOSTIC ANTIGENS OF TRYPANOSOMA CRUZI
$317K—
Sep 30, 1994NIHSBIR/STTR Phase I
DIAGNOSTIC ANTIGENS OF TRYPANOSOMA CRUZI
$75K—
Sep 15, 1994NIHSBIR/STTR Phase I
DEVELOPMENT OF LEISHMANIAL ANTIGENS AS DIAGNOSTICS
$75K—
Sep 15, 1994NIHSBIR/STTR Phase II
DEVELOPMENT OF LEISHMANIAL ANTIGENS AS DIAGNOSTICS
$315K—
Sep 15, 1994NIHSBIR/STTR Phase II
DEVELOPMENT OF LEISHMANIAL ANTIGENS AS DIAGNOSTICS
$321K—
Nov 1, 1993NIHNIH R01
LEISHMANIA ANTIGENS DEFINES BY HUMAN IMMUNE RESPONSES
$239K—
Among 1,601 researchers in this sector

Peer ranks

Federal funding#145
Awards as PI#24
Patents#27
From filings, awards and patents

Companies

No tracked company linked yet.

Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.